To read the full story, subscribe or sign in.

Eisai's Halaven delivers precious months for sarcoma patients

June 2, 2015

CHICAGO – The first randomized phase III study to show an overall survival benefit in patients with the aggressive soft-tissue sarcomas was unveiled Saturday at the ASCO annual meeting.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 14, 2025.

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BioWorld

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...

BD’s biosciences & diagnostics unit in $17.5B merger with Waters

BioWorld MedTech

Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...

Ultragenyx hit again, this time with a CRL in rare disease

BioWorld

Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle...